Literature DB >> 17183188

Renal protective role of atrial natriuretic peptide in acute sodium overload-induced inflammatory response.

María Inés Rosón1, Jorge E Toblli, Silvana L Della Penna, Susana Gorzalczany, Marcela Pandolfo, Susana Cavallero, Belisario E Fernández.   

Abstract

BACKGROUND: The present study was performed to explore the effect of exogenous infusions of atrial natriuretic peptide (ANP) on the early inflammatory response during acute sodium overload in normal rats.
METHODS: Sprague Dawley rats were exposed to acute sodium overload (Na 1.5 M). Nonhypotensive doses of ANP (1 and 5 microg x kg(-1) x h(-1)) were infused simultaneously with sodium or after sodium infusion in order to evaluate prevention or reversion of the inflammatory response, respectively. We determined inflammation markers in renal tissue by immunohistochemistry.
RESULTS: Creatinine clearance was not reduced in any case. Sodium tubular reabsorption increased after sodium overload (334.3 +/- 18.7 vs. control 209.6 +/- 27.0 mEq x min(-1), p < 0.05) without changes in mean arterial pressure. This increase was prevented (228.9 +/- 26.4; p < 0.05) and reversed (231.5 +/- 13.9; p < 0.05) by ANP-5 microg x kg(-1) x h(-1). Sodium overload increased the expression of: RANTES (38.4.3 +/- 0.8 vs. 2.9 +/- 0.6%, p < 0.001), transforming-growth-factor-beta(1) (35.3 +/- 1.0 vs. 5.0 +/- 0.7%, p < 0.001), alpha-smooth muscle actin (15.6 +/- 0.7 vs. 3.1 +/- 0.3%, p < 0.001), NF-kappaB (9.4 +/- 1.3 to 2.2 +/- 0.5 cells/mm(2), p < 0.001), HIF-1alpha (38.2 +/- 1.7 to 8.4 +/- 0.8 cells/mm(2), p < 0.001) and angiotensin II (35.9 +/- 1.3 to 8.2 +/- 0.5%, p < 0.001). ANP-5 microg x kg(-1) x h(-1) prevented and reversed inflammation: RANTES (9.2 +/- 0.5 and 6.9 +/- 0.7, p < 0.001); transforming growth factor-beta(1) (13.2 +/- 0.7 and 10.2 +/- 0.5, p < 0.001) and alpha-smooth muscle actin (4.1 +/- 0.4 and 5.2 +/- 0.4, p < 0.001). Both prevention and reversion by ANP were associated with downregulation of NF-kappaB (3.2 +/- 0.4 and 2.8 +/- 0.5, p < 0.001) and angiotensin II (8.2 +/- 0.5 and 9.1 +/- 0.7, p < 0.001) and diminished hypoxia evaluated through HIF-1alpha expression (8.4 +/- 0.8 and 8.8 +/- 0.7, p < 0.001).
CONCLUSION: Our study provides evidence supporting a protective role of ANP in both prevention and reversion of renal inflammation in rats with acute sodium overload. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17183188     DOI: 10.1159/000098148

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  4 in total

1.  LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Authors:  Wanghui Jing; Nosratola D Vaziri; Ane Nunes; Yasunori Suematsu; Ted Farzaneh; Mahyar Khazaeli; Hamid Moradi
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Inflammation and Circulating Natriuretic Peptide Levels.

Authors:  Hannah Fish-Trotter; Jane F Ferguson; Nirav Patel; Pankaj Arora; Norrina B Allen; Katherine N Bachmann; Lori B Daniels; Muredach P Reilly; Joao A C Lima; Thomas J Wang; Deepak K Gupta
Journal:  Circ Heart Fail       Date:  2020-06-08       Impact factor: 8.790

3.  Renal overexpression of atrial natriuretic peptide and hypoxia inducible factor-1α as adaptive response to a high salt diet.

Authors:  Silvana Lorena Della Penna; Gabriel Cao; Andrea Carranza; Elsa Zotta; Susana Gorzalczany; Carolina Susana Cerrudo; Natalia Lucía Rukavina Mikusic; Alicia Correa; Verónica Trida; Jorge Eduardo Toblli; María Inés Rosón; Belisario Enrique Fernández
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

4.  The heme oxygenase system suppresses perirenal visceral adiposity, abates renal inflammation and ameliorates diabetic nephropathy in Zucker diabetic fatty rats.

Authors:  Joseph Fomusi Ndisang; Ashok Jadhav; Manish Mishra
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.